Stefano Molica

5.5k total citations
170 papers, 3.0k citations indexed

About

Stefano Molica is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Stefano Molica has authored 170 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 147 papers in Genetics, 108 papers in Pathology and Forensic Medicine and 53 papers in Immunology. Recurrent topics in Stefano Molica's work include Chronic Lymphocytic Leukemia Research (143 papers), Lymphoma Diagnosis and Treatment (108 papers) and Immunodeficiency and Autoimmune Disorders (45 papers). Stefano Molica is often cited by papers focused on Chronic Lymphocytic Leukemia Research (143 papers), Lymphoma Diagnosis and Treatment (108 papers) and Immunodeficiency and Autoimmune Disorders (45 papers). Stefano Molica collaborates with scholars based in Italy, United Kingdom and United States. Stefano Molica's co-authors include Domenico Levato, Luciano Levato, Gaetano Vitelli, Diana Giannarelli, A Dattilo, Fortunato Morabito, Doménico Ribatti, Angelo Vacca, Pellegrino Musto and Vincenzo Liso and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Stefano Molica

167 papers receiving 2.9k citations

Peers

Countries citing papers authored by Stefano Molica

Since Specialization

Citations

This map shows the geographic impact of Stefano Molica's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefano Molica with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefano Molica more than expected).

Fields of papers citing papers by Stefano Molica

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefano Molica. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefano Molica. The network helps show where Stefano Molica may publish in the future.

Co-authorship network of co-authors of Stefano Molica

This figure shows the co-authorship network connecting the top 25 collaborators of Stefano Molica. A scholar is included among the top collaborators of Stefano Molica based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefano Molica. Stefano Molica is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cardiovascular Challenges in Chronic Lymphocytic Leukemia ( CLL ) Patients Undergoing Bruton Tyrosine Kinase ( BTK ) Inhibitor Therapy 2025 ·European Journal Of Haematology ·Stefano Oliva, Stefano Molica	0
2	AMPLIFY: A second-generation BTK inhibitor for fixed-duration therapy in chronic lymphocytic leukemia 2025 ·Med ·Stefano Molica	1
3	High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition 2024 ·SHILAP Revista de lepidopterología ·Daniel S. James, (unknown), Stefano Molica, David Allsup	1
4	Real‐world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience 2023 ·Hematological Oncology ·Luca Laurenti, Lydia Scarfò, Anna Maria Frustaci, Alessandro Sanna, (unknown), Morena Caira, (unknown), (unknown), Benedetta Neri, Stefano Molica, Francesca Romana Mauro	4
5	COVID-19 Pandemic Impact on Chronic Lymphocytic Leukemia (CLL) Patients' Preferences Towards Therapies: The Italian Experience (CHOICE Study) 2021 ·Blood ·Stefano Molica, Luca Laurenti, Paolo Ghia, Marta Coscia, Antonio Cuneo, Gianluca Gaïdano, Francesca Romana Mauro, Anna Maria Frustaci, Daniele Vallisa, Fabrizio Pane, Giuliana Gualberti, (unknown), (unknown), Morena Caira, Paolo Sportoletti	1
6	Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Stefano Molica, Diana Giannarelli, Emili Montserrat	14
7	Unusual metastases of melanoma 2018 ·Clinical Case Reports ·Guido Carillio, Stefano Molica	1
8	Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers ( IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL‐IPI 2017 ·American Journal of Hematology ·Julio Delgado, Michael Doubek, Tycho Baumann, Jana Kotašková, Stefano Molica, Pablo Mozas, Alfredo Rivas‐Delgado, Fortunato Morabito, Šárka Pospı́šilová, Emili Montserrat	66
9	Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time 2016 ·Clinical Case Reports ·Stefano Molica, Guido Carillio, C Battaglia	1
10	Tolerability and Efficacy of Busulfan and Fludarabine As Allogeneic Pretransplant Conditioning Therapy in Acute Myeloid Leukemia: Comparison With Busulfan and Cyclophosphamide Regimen 2014 ·Clinical Lymphoma Myeloma & Leukemia ·Roberta Fedele, Giuseppe Messina, Tiziana Martinello, (unknown), (unknown), Tiziana Moscato, Giuseppe Console, (unknown), (unknown), Maria Cuzzola, Caterina Alati, Francesca Ronco, Stefano Molica, Giuseppe Irrera, Massimo Martino	6
11	Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs 2013 ·Clinical Lymphoma Myeloma & Leukemia ·Massimo Martino, Maurizio Postorino, (unknown), Giuseppe Messina, (unknown), Eugenio Piro, Massimo Gentile, Tiziana Moscato, (unknown), Roberta Fedele, Carla Mazzone, Giuseppe Console, Giuseppa Penna, Caterina Alati, Iolanda Donatella Vincelli, Giuseppe Irrera, Caterina Musolino, Francesca Ronco, Stefano Molica, Fortunato Morabito	12
12	The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: Results of a comparative analysis 2013 ·Leukemia Research ·Stefano Molica, Diana Giannarelli, Massimo Gentile, Giovanna Cutrona, Nicola Di Renzo, Francesco Di Raimondo, Antonino Neri, Massimo Federico, Manlio Ferrarini, Fortunato Morabito	5
13	An Increased Number of Individuals with Clinically Recognized Monoclonal B-Cell Lymphocytosis Characterizes a Recent Database of Chronic Lymphocytic Leukemia Rai Stage 0 2012 ·Acta Haematologica ·Stefano Molica, Massimo Gentile, Francesca Romana Mauro, Maura Brugiatelli, Massimo Federico, Isabella Sperduti, Antonino Neri, Manlio Ferrarini, Robin Foà, Fortunato Morabito	3
14	Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion 2010 ·Clinical Cancer Research ·Laura Mosca, Sonia Fabris, Marta Lionetti, Katia Todoerti, Luca Agnelli, Fortunato Morabito, Giovanna Cutrona, Adrian Andronache, Serena Matis, Francesco Ferrari, Massimo Gentile, Mauro Spriano, Vincenzo Callea, Gianluca Festini, Stefano Molica, Giorgio La Nasa, Silvio Bicciato, Manlio Ferrarini, Antonino Neri	38
15	Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia? 2009 ·Advances in Hematology ·Stefano Molica, Giovanna Digiesi, Angelo Vacca, (unknown), Katia Todoerti, C Battaglia, Fortunato Morabito, Antonino Neri, Doménico Ribatti	5
16	Serum level of CD26 predicts time to first treatment in early B‐chronic lymphocytic leukemia 2009 ·European Journal Of Haematology ·Stefano Molica, Giovanna Digiesi, (unknown), Giovanna Cutrona, Anna Antenucci, Matteo Molica, Diana Giannarelli, Isabella Sperduti, Fortunato Morabito, Antonino Neri, Luca Baldini, Manlio Ferrarini	11
17	Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia 2008 ·Leukemia & lymphoma ·Stefano Molica, Gaetano Vitelli, Giovanna Cutrona, Katia Todoerti, (unknown), Giovanna Digiesi, Fortunato Morabito, Antonino Neri, Manlio Ferrarini	3
18	A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia 2005 ·Leukemia & lymphoma ·Stefano Molica, Francesca Romana Mauro, Vincenzo Callea, Massimo Gentile, Diana Giannarelli, Manuela Lopez, Francesco Lauria, Bruno Rotoli, Marco Montanaro, Agostino Cortelezzi, Vincenzo Liso, Franco Mandelli, Robin Foà, (unknown)	22
19	Cytosolic carbonic anhydrase activity in chronic myeloid disorders with different clinical phenotype 2004 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Giuseppe Bonapace, Francesco Iuliano, Stefano Molica, Antonio Peta, Pietro Strisciuglio	6
20	Surface CD14 positivity in B‐cell chronic lymphocytic leukaemia is related to clinical outcome 1999 ·British Journal of Haematology ·Vincenzo Callea, Fortunato Morabito, Bianca Oliva, Caterina Stelitano, Domenico Levato, A Dattilo, (unknown), (unknown), Pasquale Iacopino, Francesco Nobile, Stefano Molica, Maura Brugiatelli	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact